Cited 16 times in
A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명수 | - |
dc.date.accessioned | 2022-09-06T06:05:23Z | - |
dc.date.available | 2022-09-06T06:05:23Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 1091-255X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190156 | - |
dc.description.abstract | Background Although invasive fungal infections (IFIs) contribute to substantial morbidity and mortality in liver transplant recipients, only a few randomized studies analyzed the results of antifungal prophylaxis with echinocandins. The aim of this open-label, non-inferiority study was to evaluate the efficacy and safety of micafungin in the prophylaxis of IFIs in living-donor liver transplantation recipients (LDLTRs), with fluconazole as the comparator. Methods LDLTRs (N = 172) from five centers were randomized 1:1 to receive intravenous micafungin 100 mg/day or fluconazole 100~200 mg/day (intravenous or oral). A non-inferiority of micafungin was tested against fluconazole. Results The per-protocol set included 144 patients without major clinical trial protocol violations: 69 from the micafungin group and 75 from the fluconazole group. Mean age of the study patients was 54.2 years and mean model for end-stage liver disease (MELD) score amounted to 16.5. Clinical success rates in the micafungin and fluconazole groups were 95.65% and 96.10%, respectively (difference: - 0.45%; 90% confidence interval [CI]: - 6.93%, 5.59%), which demonstrated micafungin's non-inferiority (the lower bound for the 90% CI exceeded - 10%). The study groups did not differ significantly in terms of the secondary efficacy endpoints: absence of IFIs at the end of the prophylaxis and the end of the study, time to proven IFI, fungal-free survival, and adverse reactions. A total of 17 drug-related adverse events were observed in both groups; none of them was serious and all resolved. Conclusion Micafungin can be used as an alternative to fluconazole in the prevention of IFIs in LDLTRs. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | JOURNAL OF GASTROINTESTINAL SURGERY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antifungal Agents / therapeutic use | - |
dc.subject.MESH | End Stage Liver Disease* | - |
dc.subject.MESH | Fluconazole / therapeutic use | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Invasive Fungal Infections* / drug therapy | - |
dc.subject.MESH | Lipopeptides | - |
dc.subject.MESH | Liver Transplantation* / adverse effects | - |
dc.subject.MESH | Living Donors | - |
dc.subject.MESH | Micafungin | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mycoses* | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.title | A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Woo-Hyoung Kang | - |
dc.contributor.googleauthor | Gi-Won Song | - |
dc.contributor.googleauthor | Sung-Gyu Lee | - |
dc.contributor.googleauthor | Kyung-Suk Suh | - |
dc.contributor.googleauthor | Kwang-Woong Lee | - |
dc.contributor.googleauthor | Nam-Joon Yi | - |
dc.contributor.googleauthor | Jae Won Joh | - |
dc.contributor.googleauthor | Choon Hyuck David Kwon | - |
dc.contributor.googleauthor | Jong Man Kim | - |
dc.contributor.googleauthor | Dong Lak Choi | - |
dc.contributor.googleauthor | Joo Dong Kim | - |
dc.contributor.googleauthor | Myoung Soo Kim | - |
dc.identifier.doi | 10.1007/s11605-019-04241-w | - |
dc.contributor.localId | A00424 | - |
dc.relation.journalcode | J01418 | - |
dc.identifier.eissn | 1873-4626 | - |
dc.identifier.pmid | 31066013 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s11605-019-04241-w | - |
dc.subject.keyword | Micafungin | - |
dc.subject.keyword | Fluconazole | - |
dc.subject.keyword | Prophylaxis of invasive fungal infection | - |
dc.subject.keyword | Living donor liver transplantation | - |
dc.contributor.alternativeName | Kim, Myoung Soo | - |
dc.contributor.affiliatedAuthor | 김명수 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 832 | - |
dc.citation.endPage | 840 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROINTESTINAL SURGERY, Vol.24(4) : 832-840, 2020-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.